



**Figure S5. Downregulation of EREG re-sensitized NSCLC to chemo-drugs through ERK signaling.** (A) The cell viability of *shEREG*-A549-CR cells treated with 4  $\mu$ g/mL cisplatin for 48h, n=3. (B) The cell viability of *shEREG*-A549 cells treated with serial cisplatin for 48h, n=3. (C) The sphere forming of *shEREG*-H1299 cells treated with 4  $\mu$ g/mL cisplatin, n=3. TR, taxol resistance; CR, cisplatin resistance; n.s., no significance; \*, p< 0.05; \*\*, p<0.01.